Carbon Nanotubes Target Tumors

The CCNE-TR team began by coating commercially available SWCNTs with PEG, a biocompatible polymer used frequently in drug delivery applications to increase circulation lifetimes and water solubility. The investigators used PEG of two different lengths, producing coated SWCNTs of 1 nanometer in diameter/100 nanometers in length or 5 nanometers in diameter/300 nanometers in length.

The researchers then attached a tumor-targeting peptide known as cyclic-RGD to the end of the PEG chains. RGD, short for the arginine, glycine, and aspartic acid amino acids that make up this peptide, binds to the protein æ_vß₃, which is found on the surface of certain types of malignant cells. Each nanotube contained multiple cyclic-RGD targeting molecules.

To track the nanotubes in living animals, the researchers also attached to the PEG chains multiple copies of a molecule, known as DOTA, that will bind to various metal ions. In this case, the investigators used the DOTA molecules to bind a radioactive isotope of copper, 64Cu, which can be imaged using positron emission tomography (PET). Stability assays showed all of these add-ons remained firmly attached to the nanotubes even after heating them to 70°C for more than one week.

The investigators injected a solution of this nanotube into mice bearing tumors that express æ_vß₃ on their surfaces and used PET to track the fate of the nanotubes over the next 24 hours. This experiment showed that 10 to 15 percent of the SWCNTs coated with the larger PEG molecules accumulated within tumors. Uptake was rapid, reaching a maximum within 6 hours after injection.

In contrast, only 3 to 4 percent of the nanotubes coated with the smaller PEG molecules accumulated in tumors. The investigators were able to confirm the presence of the targeted SWCNTs in tumors using Raman spectroscopy, which can detect the unique optical signals emitted by these nanotubes.

This work, which was funded by the National Cancer Institute’s Alliance for Nanotechnology in Cancer, appears in a paper titled, “In vivo biodistribution and highly efficient tumour targeting of carbon nanotubes in mice.” An abstract of this paper is available at the journal’s website.

Source: National Cancer Institute

Carbon Nanotubes Improve Protein Array Detection Limits
(PhysOrg.com) -- To detect cancer as early as possible, dozens of research groups are developing methods to detect trace levels of cancer-related proteins and genes in blood or other biological samples. Those efforts should get a boost thanks to new research results showing that carbon nanotubes can serve as incredibly sensitive optical labels for use in a wide variety of assay systems.
New Nanotube Findings Give Boost to Potential Biomedical Applications
Carbon nanotubes have shown real promise as highly accurate vehicles for delivering antitumor agents into malignant cells, but a dearth of data about what happens to the tubes after they discharge their medical payloads has been a major stumbling block to progress. Now, two studies at the Center for Cancer Nanotechnology Excellence Focused on Therapy Response have revealed some reassuring answers after months of tracking the tiny tubes inside mice.
Slipping through cell walls, nanotubes deliver high-potency punch to cancer tumors in mice
(PhysOrg.com) -- The problem with using a shotgun to kill a housefly is that even if you get the pest, you'll likely do a lot of damage to your home in the process. Hence the value of the more surgical flyswatter.
Improved culture system for hepatitis C virus infection
A University of California, San Diego School of Medicine researcher has developed the first tissue culture of normal, human liver cells that can model infection with the Hepatitis C virus (HCV) and provide a realistic environment to evaluate possible treatments. The novel cell line, described in the July 16 issue of PLoS ONE, will allow pharmaceutical companies to effectively test new drug candidates or possible vaccines for the HCV infection, which afflicts about 170 million people worldwide. Currently, there is no animal model that is effective for testing such therapies.
Study shows positive findings in treating patients with advanced hepatitis C
The hepatitis C therapy peginterferon alfa-2b, when given as low-dose maintenance therapy, can prevent disease progression in certain patients who failed previous interferon-based hepatitis C therapies and have advanced liver disease, according to findings from a large, four-year study presented today at the 43rd annual meeting of the European Association for the Study of the Liver (EASL).
New Nanoparticles for Targeting Tumors
As a wide variety of nanoparticles continue to demonstrate their ability to improve the delivery of imaging agents and drugs to tumors, nanoparticle researchers have turned their attention to the challenge of systematically determining how a given nanoparticle’s physical and chemical characteristics affect its ability to target tumors. Such data could provide drug developers with guidelines to help them select the most effective type of nanoparticle for a given therapeutic or imaging application.
Nanotechnology Advances Brain Cancer Detection and Therapy
Brain cancer is one of the most aggressive and lethal of malignancies, made even more difficult to treat by the fact that most anticancer drugs have a hard time even getting to the tumors. Now, studies by three different groups of researchers show that targeted nanoparticles hold promise for solving this delivery problem.
New nanotube findings give boost to potential biomedical applications
Carbon nanotubes-cylinders so tiny that it takes 50,000 lying side by side to equal the width of a human hair-are packed with the potential to be highly accurate vehicles for administering medicines and other therapeutic agents to patients. But a dearth of data about what happens to the tubes after they discharge their medical payloads has been a major stumbling block to progress.

Carbon Nanotubes Target Tumors

Related stories:

News discussion: